Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Brousseau

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Heliyon|June 3, 2024
Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, CanadaHenintsoa Rabezanahary, Caroline Gilbert, Kim Santerre, et al.
Human Vaccines & Immunotherapeutics|December 18, 2021
COVID-19 pandemic impact on childhood vaccination coverage in Quebec, CanadaMarilou Kiely, Thowiba Mansour, Nicholas Brousseau, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 9, 2024
Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysisAshleigh R Tuite, Alison E Simmons, Monica Rudd, et al.
Vaccine|February 10, 2024
The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative dataAlicia A Grima, Jeffrey C Kwong, Lucie Richard, et al.
The Lancet. Healthy Longevity|July 17, 2023
Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, CanadaSara Carazo, Danuta M Skowronski, Marc Brisson, et al.
Vaccine|May 3, 2026
Does an off-label two-dose RotaTeq vaccine schedule translate into a higher incidence of rotavirus hospital admissions compared to the approved three-dose RotaTeq schedule? A Canadian immunization research network studyÉlise Fortin, Éliane Miron, Ramandip Grewal, et al.
The Lancet. Infectious Diseases|September 24, 2022
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control studySara Carazo, Danuta M Skowronski, Marc Brisson, et al.
Frontiers in Immunology|January 29, 2025
Impact of SARS-CoV-2 vaccination and of seasonal variations on the innate immune inflammatory responseHend Jarras, Isalie Blais, Benjamin Goyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2021
Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, CanadaSara Carazo, Denis Talbot, Nicole Boulianne, et al.
JAMA Network Open|October 14, 2022
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, CanadaSara Carazo, Danuta M Skowronski, Marc Brisson, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Heliyon|June 3, 2024
Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, CanadaHenintsoa Rabezanahary, Caroline Gilbert, Kim Santerre, et al.
Human Vaccines & Immunotherapeutics|December 18, 2021
COVID-19 pandemic impact on childhood vaccination coverage in Quebec, CanadaMarilou Kiely, Thowiba Mansour, Nicholas Brousseau, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 9, 2024
Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysisAshleigh R Tuite, Alison E Simmons, Monica Rudd, et al.
Vaccine|February 10, 2024
The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative dataAlicia A Grima, Jeffrey C Kwong, Lucie Richard, et al.
The Lancet. Healthy Longevity|July 17, 2023
Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, CanadaSara Carazo, Danuta M Skowronski, Marc Brisson, et al.
Vaccine|May 3, 2026
Does an off-label two-dose RotaTeq vaccine schedule translate into a higher incidence of rotavirus hospital admissions compared to the approved three-dose RotaTeq schedule? A Canadian immunization research network studyÉlise Fortin, Éliane Miron, Ramandip Grewal, et al.
The Lancet. Infectious Diseases|September 24, 2022
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control studySara Carazo, Danuta M Skowronski, Marc Brisson, et al.
Frontiers in Immunology|January 29, 2025
Impact of SARS-CoV-2 vaccination and of seasonal variations on the innate immune inflammatory responseHend Jarras, Isalie Blais, Benjamin Goyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2021
Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, CanadaSara Carazo, Denis Talbot, Nicole Boulianne, et al.
JAMA Network Open|October 14, 2022
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, CanadaSara Carazo, Danuta M Skowronski, Marc Brisson, et al.
Pageof 6